Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

How Atea's Clinical Flop Shakes Up the COVID-19 Pill Market

TheMotleyFool

0 0

How Atea's Clinical Flop Shakes Up the COVID-19 Pill Market

Atea Pharmaceuticals (NASDAQ: AVIR) didn't get the outcome it wanted with a phase 2 study of its oral antiviral therapy AT-527. In this Motley Fool Live video recorded on Oct. 20, Motley Fool contributors Keith Speights and Brian Orelli discuss how Atea's clinical flop shakes up the COVID-19 pill market dynamics.

Source Fool.com

Like: 0

AVIR

Share